Oppenheimer Cuts Lumos Pharma (NASDAQ:LUMO) Price Target to $17.00

Lumos Pharma (NASDAQ:LUMO – Free Report) had its target price cut by Oppenheimer from $18.00 to $17.00 in a research report sent to investors on Thursday, Benzinga reports. They currently have an outperform rating on the stock. LUMO has been the subject of a number of other research reports. HC Wainwright reiterated a buy rating […]

Related Keywords

Lumos Pharma ,Lumos Pharma Company Profile ,Greenwich Wealth Management ,Virtu Financial ,Millennium Management ,Advisor Group ,Cantor Fitzgerald ,Envestnet Asset Management Inc ,Lumos Pharma Inc ,Free Report ,Asset Management ,Get Free Report ,Lumos Pharma Daily ,Nasdaq Lumo ,Malumo ,Medical ,Lower Price Target ,Oppenheimer Holdings Inc ,